Q-omics provides the consensus-scored RPS15AP36 profile across patient tissues and cancer cell-line models. RPS15AP36 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RPS15AP36 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, RPS15AP36 RNA expression shows 15,621 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where RPS15AP36 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS15AP36 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS15AP36 survival associations across molecular data types. RPS15AP36 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS15AP36 RNA expression–survival associations across cancer types. High RPS15AP36 expression shows unfavorable associations in UVM and LGG, but favorable associations in HNSC, KIRP, UCEC and ACC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RPS15AP36 RNA expression.
This table summarizes RPS15AP36 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS15AP36. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS15AP36 shows lower tumor expression in THCA and higher tumor expression in KIRC, LIHC, BRCA, HNSC and BLCA. The KIRC box plot shows higher RPS15AP36 RNA expression in tumor versus normal tissue (log2 FC = +0.404, t-test p < 0.001).
This table shows molecular features associated with RPS15AP36 in patient tissues and cancer cell lines. In patient samples, RPS15AP36 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
